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http://dx.doi.org/10.1016/j.ccr.2012.06.001SUMMARYThe ALKF1174L mutation is associated with intrinsic and acquired resistance to crizotinib and cosegregates
with MYCN in neuroblastoma. In this study, we generated a mouse model overexpressing ALKF1174L in the
neural crest. Compared to ALKF1174L and MYCN alone, co-expression of these two oncogenes led to the
development of neuroblastomas with earlier onset, higher penetrance, and enhanced lethality. ALKF1174L/
MYCN tumors exhibited increased MYCN dosage due to ALKF1174L-induced activation of the PI3K/AKT/
mTOR andMAPK pathways, coupled with suppression of MYCN pro-apoptotic effects. Combined treatment
with the ATP-competitive mTOR inhibitor Torin2 overcame the resistance of ALKF1174L/MYCN tumors to cri-
zotinib. Our findings demonstrate a pathogenic role for ALKF1174L in neuroblastomas overexpressingMYCN
and suggest a strategy for improving targeted therapy for ALK-positive neuroblastoma.INTRODUCTION
Neuroblastoma, an embryonal tumor derived from the neural
crest, is the most common extracranial solid tumor of childhood
(National Cancer Institute, 2005). It arises from sympathetic gan-
glia and adrenal glands, manifesting as thoracic, paraspinous or
abdominal tumors, with metastases to bone and bone marrow in
high-risk cases. Despite considerable success in the treatment
of favorable-biology neuroblastoma, 5-year survival rates forSignificance
TheALKF1174Lmutation has particular relevance in cancer, not
causes resistance to crizotinib in ALK-rearranged tumors in ge
by cooperation between ALKF1174L and MYCN should provide
MYCN interactions and for screening candidate agents for th
pathways. Our therapeutic strategy of combined ALK and mT
with ALKF1174L-positive tumors who exhibit de novo resistanc
crizotinib-sensitive ALK aberrations that acquire resistance afchildren with high-risk disease, which accounts for over half
of all newly diagnosed cases, seldom exceed 40% (Matthay
et al., 1999). A typical feature of high-risk neuroblastoma is am-
plification ofMYCN, an oncogene encoding a pleiotropic nuclear
phosphoprotein in the MYC family of helix-loop-helix transcrip-
tion factors (Schwab et al., 1984). MYCN amplification is the
major genetic aberration associated with aggressive tumor
phenotype and poor outcome in neuroblastoma (Brodeur et al.,
1984; Seeger et al., 1985). Targeted expression of MYCN toonly because of its role in neuroblastoma, but also because it
neral. Our murine model of high-risk neuroblastoma defined
an ideal platform for further dissection of oncogenic ALK-
eir ability to inhibit ALK oncoproteins and related signaling
OR inhibition may benefit not only neuroblastoma patients
e, but perhaps also patients with other cancers expressing
ter a favorable initial response.
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Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomathe neural crest in transgenicmice causes aggressive neuroblas-
tomas and tumorigenesis is positively correlated with MYCN
transgene dosage or with the development of additional genetic
mutations (Hansford et al., 2004; Weiss et al., 1997). Direct inhi-
bition of MYCN has not yet been clinically successful, thus much
attention is being directed to the therapeutic targeting of mole-
cules that modulate the activities of this potent oncoprotein.
We and others have identified activating point mutations in
the anaplastic lymphoma receptor tyrosine kinase gene (ALK)
in approximately 8% of primary neuroblastomas (Chen et al.,
2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse´
et al., 2008). In our study, these mutations converted IL-3-
dependent Ba/F3 cells to cytokine-independent growth, led to
constitutive phosphorylation of ALK and downstream signaling,
and were sensitive to the small-molecule ALK inhibitor,
TAE684 (George et al., 2008). Drug-induced cytotoxicity was
associated with decreased phosphorylation of ALK and its
downstream effectors and with the induction of apoptosis. Inhi-
bition of ALK expression in neuroblastoma cells harboring
ALK mutations resulted in a similar apoptotic phenotype and
impaired cell proliferation. Together, these studies suggested
that ALK mutations may afford therapeutic targets in high-risk
neuroblastoma, thus leading to early phase clinical trials of
crizotinib, an ALK/MET inhibitor that has been FDA approved
for use in adults with ALK-translocated cancers (Butrynski
et al., 2010; Kwak et al., 2010).
Of several somatic activating ALK mutations identified in
neuroblastomas, one of the more common is a cytosine-to-
adenine change in exon 23, resulting in a phenylalanine-to-
leucine substitution at codon 1174 (F1174L) within the kinase
domain (Chen et al., 2008; George et al., 2008; Janoueix-Lerosey
et al., 2008; Mosse´ et al., 2008). This mutation appears to be
more potent than the others, correlating with a higher degree
of autophosphorylation and greater transforming capacity.
Moreover, it is preferentially associated withMYCN gene ampli-
fication in neuroblastoma and defines a subset of ultra-high-risk
neuroblastoma patients with distinctly poor outcome (De
Brouwer et al., 2010). Finally, ALKF1174L represents one of the
sites of secondary kinase domain mutations in cases of ALK-
rearranged cancers that have become resistant to crizotinib
treatment (Sasaki et al., 2010). In particular, cell line and xeno-
graft models of human neuroblastoma with ALKF1174L expres-
sion are only minimally sensitive to crizotinib (Bresler et al.,
2011), suggesting that effective targeting of ALKF1174L will
require innovative means of combating crizotinib resistance or
perhaps the development of ALK inhibitors with alternative
mechanisms of action.
To determine the pathogenic consequences of ALKF1174L-
MYCN interactions in neuroblastoma and to identify strategies
that might overcome the resistance of these tumors to crizotinib,
we engineered a transgenic mouse model that overexpresses
both molecules in neural crest-derived cells.
RESULTS
Generation of the Th-ALKF1174 Transgenic Tumor Model
To generate mice that overexpress ALKF1174L in the neural
crest, we injected blastocysts from the C57BL/6J strain with a
Th-ALKF1174L construct in which human ALKF1174L cDNA was118 Cancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc.ligated downstream of the rat tyrosine hydroxylase (Th) promoter
(Banerjee et al., 1992) (Figure 1A; Figure S1A available online).
Th is expressed in committed sympathetic precursor cells of
the neural crest, and this tissue specificity has facilitated efforts
to targetMYCN overexpression to neuroectodermal cells result-
ing in tumors that arise in the sympathetic ganglia and adrenal
gland (Weiss et al., 1997). We verified expression of the human
ALKF1174L protein in 293T cells, which lack endogenous expres-
sion of ALK (Figure S1B). Germline positivity for the transgene
was demonstrated in multiple founders by PCR genotyping
of tail DNA. Tissue-specific expression of ALKF1174L and of
the endogenous wild-type (WT) murine Alk was confirmed by
RT-PCR followed by sequencing of cDNA in the cervical sympa-
thetic ganglia and adrenal glands of 7- to 10-day-old mice
(Figure 1B). In four distinct founder lines, ALKF1174L was trans-
mitted in Mendelian ratios and produced no apparent phenotype
in either hemi- or homozygotes, not only in the C57BL/6J
background but also in the more ‘‘tumor-permissive’’ 129X1/
SvJ strain.
Overexpression of ALKF1174L Potentiates the Oncogenic
Activity of MYCN In Vivo
A meta-analysis of ALK mutations in human neuroblastoma
suggested that ALKF1174L may play a role in promoting aggres-
sive tumors in cooperation withMYCN amplification (DeBrouwer
et al., 2010). Otherwise, evidence to support a functional interac-
tion between MYCN and ALKF1174L in vivo is lacking. We there-
fore investigated the effect of co-expression of ALKF1174L and
MYCN in neuroblastoma by crossing Th-ALKF1174L mice with
Th-MYCN mice (Weiss et al., 1997). Mice hemizygotic for
both ALKF1174L and MYCN exhibited high tumor penetrance
with rapid lethality superior to that observed in MYCN hemizy-
gotes (Figures 1C and 1D; Table 1). Of the four Th-ALKF1174L
founder lines that were crossed with Th-MYCN mice, the
offspring of founders 2 and 4 showed complete tumor pene-
trance, shorter median time to tumor onset, and decreased
survival at 100 days of age compared to that of Th-MYCN
animals (Figure 1C and Table 1). An additional pattern of
complete penetrance with longer latency was obtained in
founder lines 1 and 3 (Figure 1D and Table 1). All subsequent
experiments described in this study were performed using
offspring of founders 2 and 4.
Co-expression of ALKF1174L and MYCN (ALKF1174L/MYCN
compound hemizygotes) led to the development of large, bulky
and locally invasive thoracic and abdominal masses that arose
in the paraspinal ganglia or adrenals, locations typically seen in
human neuroblastoma (Figure 2A). In contrast to MYCN tumors
that generally arise as single primary tumors, the ALKF1174L/
MYCN tumors manifested as large, synchronous primary
masses (Figure 2A). Focal masses on the forelimb, neck, and
shoulder were seen in a minority of animals (data not shown).
No evidence of macroscopic tumor spread to other organs
(skin, liver, kidney, brain and lung) was detected. Tumor bearing
mice exhibited normal peripheral blood counts (data not shown)
and immunostaining of bone marrow cytospins for expression of
the neural crest marker tyrosine hydroxylase (TH) revealed no
evidence of bone marrow metastasis (Figure S2A). The tumors
exhibited robust expression of ALK and MYCN at both the
RNA and protein levels (Figures 2B and 2C) and also expressed
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Figure 1. Overexpression of ALKF1174L
Potentiates the Oncogenic Activity of
MYCN In Vivo
(A) The ALKF1174L cDNA was ligated 30 to the rat
Th promoter to generate the p4.5 Th-ALKF1174L
transgenic construct (Th-ALKF1174L).
(B) RT-PCR analysis of ALK expression in cervical
ganglia and adrenal glands of 7 to 10-day-old WT
mice (M4-M6) or mice transgenic for ALKF1174L
(M1-M3) (left panels). Spl, spleen. Electrophero-
gram showing the change in the phenylalanine
codon (TTC) in WT ALK to leucine (CTC) in the
ALKF1174L mutation in ganglia (right panel).
(C and D) Kaplan-Meier survival curves of
founder lines resulting from intercrosses of
Th-ALKF1174L mice and Th-MYCN mice. (C)
Founder 2 - ALKF1174L/MYCN, n = 31; MYCN,
n = 9; ALKF1174L, n = 4; WT, n = 5. Founder
4 - ALKF1174L/MYCN, n = 25; MYCN, n = 20;
ALKF1174L, n = 13; WT, n = 6. (D) Founder
1 - ALKF1174L/MYCN, n = 12; MYCN, n = 6;
ALKF1174L, n =12;WT, n = 3. Founder 3 -ALKF1174L/
MYCN, n = 11; MYCN, n = 10; ALKF1174L, n = 11;
WT, n = 5.
See also Figure S1.
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Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomaphosphorylated ALKF1174L (Figure 2C). Similar to genotypically
verified human neuroblastoma tumors expressing both
ALKF1174L and MYCN, histologically, the doubly transgenic
murine tumors displayed characteristic dense aggregates of
poorly differentiated small round blue cells with high mitotic
activity in a stroma-poor background (Figure 2D). Both human
and murine tumors had similar immunohistochemical profiles
of high-level cytoplasmic ALK and nuclear MYCN protein
expression (Figure 2D). Positive staining for markers of human
neuroblastoma, such as synaptophysin, was also evident (Fig-
ure S2B). These results demonstrate the ability of constitutively
expressed ALKF1174L to enhance MYCN-driven oncogenesis.
Importantly, the early onset and rapid lethality of ALKF1174L/
MYCN murine tumors are characteristic of the clinical course
of high-risk neuroblastoma in humans (De Brouwer et al., 2010)
and thus they provide a suitable model in which to dissect
ALKF1174L/MYCN interactions in vivo.Cancer Cell 22, 117–ALKF1174L/MYCN Tumors Show
Differential Activation of Signal
Transduction Pathways
To further characterize the aggressive
nature of ALKF1174L/MYCN tumors, we
analyzed the transcriptional profiles of
MYCN-positive tumors with or without
ALKF1174 expression. ALKF1174L/MYCN
and MYCN tumors exhibited distinct
genetic profiles; of the 684 genes that
were differentially expressed, 476 were
upregulated in ALKF1174L/MYCN tumors
(Figure 3A). Gene set enrichment anal-
ysis (GSEA) indicated significant upre-
gulation of genes involved in the PI3K/
AKT/mTOR and MAPK signal transduc-
tion pathways in ALKF1174L/MYCN com-pared to MYCN tumors (Figure 3B), suggesting increased
utilization of these two pathways in neuroblastoma cells consti-
tutively expressing ALKF1174L together with MYCN. This was
supported by immunoblot analysis showing greater phosphory-
lation of AKT, as well as activation of components of the MAPK
pathway, MEK and ERK, in ALKF1174L/MYCN versus MYCN
tumor cells (Figure 3C). These differences in activation of down-
stream signaling were confirmed also by immunohistochemical
staining, which in addition showed upregulated mTOR activity
as determined by pS6 kinase expression (Figure 3D). Similar
upregulation of pS6K and pERK were seen in human
ALKF1174L/MYCN-expressing tumors compared to those with
MYCN overexpression only (Figure 3D). Moreover, a number
of kinase-associated docking proteins, such as the Src
homology 2 domain-containing adaptor molecules GRB2,
IRS1 and IRS2, were significantly upregulated in ALKF1174L/
MYCN tumors (Figure S3). Together, these data attest to the130, July 10, 2012 ª2012 Elsevier Inc. 119
Table 1. Transgenic Lines Resulting from Th-ALKF1174L and
Th-MYCN Intercrosses
Founder
Linea Genotypes
Number
of Animals
Penetrance
(%)
Latency (days),
Median (range)
1 Th-ALKF1174L/
MYCN
12 100 80 (44–185)
Th-MYCN 6 0 –
Th-ALKF1174L 12 0 –
Th-ALKF1174L/
ALKF1174L
22 0 –
WT 3 0 –
2 Th-ALKF1174L/
MYCN
31 100b 42 (32–98)c
Th-MYCN 9 25 76 (67–88)
Th-ALKF1174L 4 0 –
Th-ALKF1174L/
ALKF1174L
8 0 –
WT 5 0 –
3 Th-ALKF1174L/
MYCN
11 100 83 (68–163)
Th-MYCN 10 0 –
Th-ALKF1174L 11 0 –
WT 5 0 –
4 Th-ALKF1174L/
MYCN
25 100b 39 (28–93)c
Th-MYCN 20 35 79 (39–96)
Th-ALKF1174L 13 0 –
Th-ALKF1174L/
ALKF1174L
10 0 –
WT 6 0 –
aFour ALKF1174L founder lines exhibited neural tissue-specific overex-
pression of ALKF1174L (adrenal tissue and superior cervical ganglia).
ALKF1174L (C57BL/6J) andMYCN (129X1/SvJ) hemizygotes were serially
intercrossed into the permissive 129X1/SvJ strain. F1 MYCN offspring
were not tumor prone, but regained 25%–35% penetrance at 100 days
in F3–F4, consistent with expectations for this strain background
(75%–94% 129X1/SvJ).
bSignificantly different from penetrance in mice expressing Th-MYCN
(p < 0.0001 by Student’s t test).
cSignificantly different from median (range) days to tumor onset in mice
expressing Th-MYCN (p < 0.0001 by Student’s t test).
Cancer Cell
Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomapredominance of these signaling networks in ALKF1174L/MYCN
tumors in comparison to MYCN tumors.
ALKF1174L Enhances MYCN Protein Stabilization
Given the roles of both the PI3K/AKT/mTOR and MAPK path-
ways in post-translational modification of MYCN (Chesler
et al., 2006; Gustafson and Weiss, 2010; Marshall et al., 2011),
we determined the consequences of their activation on MYCN
protein stability in the double transgenic tumors. Indeed, higher
levels of MYCN were apparent in ALKF1174L/MYCN versus
MYCN tumors by immunohistochemical staining but not by
immunoblotting (Figures 4A and 4D). To clarify whether
ALKF1174L expression influenced MYCN protein levels, we abro-
gated expression of ALKF1174L in the Kelly human neuroblastoma
cell line, which expresses high levels of both genes. Small inter-120 Cancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc.fering RNA (siRNA) knockdown of ALKF1174L expression led to
a decreasedMYCN protein level in these cells (Figure 4B). More-
over, the half-life of MYCN protein was reduced from 90-120min
to 30 min when ALKF1174L was depleted by shRNA knockdown,
suggesting that ALKF1174L plays a role in reducing MYCN protein
turnover (Figure 4C). To determine whether MYCN stability was
enhanced in ALKF1174L/MYCN tumors, we analyzed the phos-
phorylation of serine 62 (S62) and threonine 58 (T58), which
regulate MYCN protein stability (Gustafson and Weiss, 2010;
Sjostrom et al., 2005). We observed decreased pMYCNT58 levels
in ALKF1174L/MYCN tumors compared to MYCN tumors (Fig-
ure 4D). Increased PI3K pathway activity is thought to oncogeni-
cally stabilize MYCN in neuroblastoma cells by inactivating
glycogen synthase kinase 3b (GSK3b), which mediates phos-
phorylation of MYCN at T58 (Chesler et al., 2006; Gustafson
and Weiss, 2010). The same process appears to occur in
ALKF1174L/MYCN tumors, where GSK3b is phosphorylated
(inactivated), in contrast toMYCN tumors (Figure 4D). pMYCNT58
then binds to the E3 ligase FBXW7 and is targeted for ubiquitina-
tion and degradation (Otto et al., 2009). Using a dual-link anti-
body ligation assay to detect direct physical interactions
between MYCN and FBXW7, we observed that knockdown of
ALKF1174L in Kelly cells led to increased interactions between
the two proteins, further attesting to the role of this mutant in
mediating decreased pMYCNT58 levels (Figure 4E). Thus, by
promoting greater stabilization of MYCN, constitutive signaling
mediated by ALKF1174L appears to increase MYCN dosage in
the ALKF1174L/MYCN transgenic tumor model.
Upregulation of Endogenous Mycn RNA
in ALKF1174L/MYCN Tumors
A striking observation in the transcriptional signatures was
the markedly increased expression of endogenous Mycn in
ALKF1174L/MYCN versus MYCN tumors; in fact, murine Mycn
was among the top 25 significantly upregulated genes in our
expression arrays (Figure 5A). To pursue this observation, we
used qRT-PCR to measure levels of human MYCN and murine
Mycn in the ALKF1174L/MYCN tumors. While there was no signif-
icant difference between the levels of transgenic human MYCN
in the two types of tumor, the expression of mouse Mycn RNA
was indeed elevated in the ALKF1174L/MYCN tumors, equivalent
to expression levels of transgenic human MYCN (Figure 5B).
There was no evidence of amplification of either oncogene on
FISH analysis (Figure 5C), eliminating this mechanism as a cause
of increased Mycn expression. To determine whether ALKF1174L
has a role in modulatingMYCN expression, we measuredMYCN
mRNA levels in Kelly cells upon knockdown of ALKF1174L and
observed a decrease in MYCN mRNA levels (Figure 5D). This
suggests that the constitutively activated ALK mutant may also
regulate transcription of MYCN.
ALKF1174L Activates an Anti-Apoptotic Program
in the ALKF1174L/MYCN Tumors
Ectopic expression of MYCN sensitizes cells to undergo
apoptosis (Pelengaris et al., 2002). This means that efficient
transformation by MYCN would require concomitant inhibition
of apoptosis. Although bothALKF1174L/MYCN andMYCN tumors
exhibited similar levels of proliferation by Ki-67 staining, the
amount of apoptosis as determined by TUNEL and cleaved
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Figure 2. Combined Overexpression of ALKF1174L and MYCN Results in Multifocal Neuroblastomas
(A) Gross appearance of representative ALKF1174L/MYCN andMYCN tumors. Tumors (*) arise as multifocal primary lesions in ALKF1174L/MYCN animals: thoracic
paraspinous (left panel) and abdominal (right panel) tumors. K, kidney; L, liver; Lu, Lung.
(B) Quantitative RT-PCR analysis of murine and human ALK expression in spleen, adrenal glands and tumors from ALKF1174L/MYCN orMYCN mice. Error bars
indicate mean values ± 95% confidence interval (CI).
(C) Immunoblotting of ALKF1174L/MYCN tumors (T, M1-M6) for ALK, MYCN (left panel) and pALK (right panel). pALK was detected using a human-specific
ALKY1604 antibody. Matched spleens (S) were used as negative controls and GAPDH was used as a loading control.
(D) H&E and immunohistochemical staining for ALK andMYCN of representativeALKF1174L/MYCNmurine and human neuroblastoma tumor sections. Scale bars,
20 mm, insets 5 mm.
See also Figure S2.
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Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomacaspase-3 staining was greatly reduced in the ALKF1174L/MYCN
versus MYCN tumors (Figures 6A and S4). Similar differences
were noted between human neuroblastoma tumors that were
positive for both ALKF1174 andMYCN and those that were posi-
tive for MYCN only (Figure 6A). These findings suggest thatconstitutive expression of ALKF1174L reduces apoptosis caused
by MYCN overexpression. To test this hypothesis, we examined
the gene expression profiles of these tumors, noting that expres-
sion of Trp53was downregulated in theALKF1174L/MYCN tumors
versus MYCN tumors (Figure 6B). However, none of the genesCancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc. 121
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Figure 3. ALKF1174L/MYCN Tumors Exhibit Distinct Expression Profiles and Downstream Signaling Compared to MYCN Tumors
(A) Heat map representation of differentially regulated genes in ALKF1174L/MYCN versus MYCN tumors (fold changeR 2.0; corrected p value < 0.05).
(B) GSEA of PI3K/AKT/mTOR and MAPK pathway genes in transcriptional profiles of ALKF1174L/MYCN and MYCN tumors. The normalized enrichment score
(NES) and the nominal p values are indicated.
(C) Immunoblotting of PI3K/AKT/mTOR and MAPK signaling pathways in ALKF1174L/MYCN and MYCN tumors.
(D) Immunohistochemical staining for PI3K/AKT/mTOR (pS6K) andMAPK (pMEK and pERK) pathways inALKF1174L/MYCN andMYCNmurine and human tumors
(Scale bars, 10 mm).
See also Figure S3.
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Figure 4. ALKF1174L Enhances MYCN Protein Stabilization
(A) Immunohistochemical staining for MYCN in ALKF1174L/MYCN and MYCN tumors. Scale bars, 20 mm.
(B) Western blot analysis of MYCN protein in Kelly human neuroblastoma cells after ALKF1174L knockdown using three different siRNAs (1, 2, and 3). Ctl, cells
expressing a control siRNA.
(C) Western blot analysis of MYCN protein expression in Kelly cells transfected with an ALK or control shRNA followed by treatment with 25 mmol/L of cyclo-
heximide (CHX) and harvested at the indicated time points.
(D) Immunoblotting of ALKF1174L/MYCN andMYCN tumors for pMYCNS62, pMYCNT58, and pGSK3b (upper panel). Graph (lower panel) depicts quantification of
pMYCNT58 expression in the two types of tumors. *p = 0.05 by unpaired t test.
(E) In situ detection of MYCN:FBXW7 complex formation (arrowheads) in untreated Kelly cells (mock control), ALKF1174L-depleted cells (siRNAs 1 and 3), or cells
probed with secondary antibody only as a negative control (antibody control). Quantification of the number of MYCN:FBXW7 interactions in untreated Kelly cells
and ALKF1174L-depleted Kelly cells (right panel). Data are presented as means ± standard deviation (SD). ***p = 0.009 (Student’s t test).
Cancer Cell
Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomaencoding proteins reported to be involved in MYCN-induced
apoptosis that regulate p53, such as MDM2, p14ARF or TWIST
(Gustafson and Weiss, 2010) were differentially expressed
between ALKF1174L/MYCN tumors and MYCN tumors (data not
shown). Since various BCL2 family members are direct tran-scriptional targets of p53 (Hemann and Lowe, 2006), we then
compared the expression of BCL2 family proteins between the
two tumor types. Both mRNA and protein levels of the pro-
survival genes Bcl2 and Bclw (Bcl2l2), but not Mcl1, were
significantly upregulated in ALKF1174L/MYCN tumors (FiguresCancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc. 123
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Figure 5. ALKF1174L Induces Expression of Endogenous Murine MYCN
(A) Heat map representing the top 50 upregulated genes (corrected p value < 0.05, fold changeR 2.0) in ALKF1174L/MYCN tumors compared withMYCN tumors.
(B) qRT-PCR analysis of murine and human MYCN expression in adrenal glands and tumors from ALKF1174L/MYCN and MYCN mice. Expression is relative to
either murine or human MYCN levels in tumors from MYCN heterozygotic mice. Mean values ± 95% CI are indicated.
(C) FISH analysis ofmurineALKF1174L/MYCN tumors using anALK dual-color break-apart probe (upper panel) and aMYCN probe (lower panel) (Scale bar, 10 mm).
(D) qRT-PCR analysis of ALKF1174L andMYCN expression in Kelly cells in which ALKF1174L expression was depleted using shRNA, compared with cells in which
a control shRNA was used. Western blot showing level of ALKF1174L knockdown (inset). Mean ± SEM values for three independent experiments are shown.
Ctl, cells expressing a control shRNA.
Cancer Cell
Mouse Model of ALKF1174L/MYCN-Positive Neuroblastoma6B–6D). The pro-apoptotic genes Bak and Bax, the latter being
a key intermediate of MYC-driven apoptosis (Hemann and
Lowe, 2006), and the BH3 pro-apoptotic genes Bik, Bid, and
Noxa were downregulated in the ALKF1174L/MYCN tumors
(Figures 6B and 6C). Together, these findings suggest that
constitutively expressed ALKF1174L contributes to MYCN-driven
neuroblastoma by exerting an anti-apoptotic effect that allows
transformed cells to evade MYCN-induced apoptosis.
Combined Inhibition of ALKF1174L and Its Downstream
Signaling Pathways Leads to Regression
of ALKF1174L/MYCN Tumors
Human neuroblastoma cells and xenograft models expressing
ALKF1174L are resistant to crizotinib (Bresler et al., 2011). To
determine if such resistance was reiterated in our neuroblastoma
model, we treated mice bearing ALKF1174L/MYCN tumors with
crizotinib. After documenting baseline tumor burden by serial
MRIs, we treated the animals for 7 days with oral vehicle or
crizotinib at a daily dose of 100 mg/kg, which has been used in
xenograft models of neuroblastoma (Bresler et al., 2011).
Despite partial dephosphorylation of ALK, crizotinib treatment
did not appear to have an effect on tumor size (Figures
7A–7C). Histologic analysis confirmed the lack of any significant
treatment effect on cellularity, while cleaved caspase-3 staining124 Cancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc.revealed no evidence of apoptosis (Figure 7D). Thus, our doubly
transgenic model recapitulates the crizotinib resistance of
human neuroblastoma and ALK-rearranged cancers.
Preclinical studies of crizotinib have shown that both pAKT
and pERK are incompletely inhibited with doses of crizotinib
that abolish ALK phosphorylation in NPM-ALK-positive lym-
phoma cells (Christensen et al., 2007). To determine whether
the lack of response to crizotinib in the ALKF1174L/MYCN tumors
could be due to persistent or even paradoxical activation of the
signaling pathways utilized by these two interacting oncopro-
teins, we analyzed the downstream effectors of the PI3K/AKT/
mTOR and MAPK pathways. Although treatment with crizotinib
led to a minimal decrease in AKT phosphorylation compared
with results for vehicle-treated animals, it lacked any discernible
effects on mTOR and MAPK signaling, as indicated by the
persistent activation of pS6K and p4E-BP1 and of pMEK and
pERK, respectively, on both western analysis and immunohisto-
chemistry (Figures 7C and 7D).
We therefore sought to determine if these tumors could be
rendered sensitive to crizotinib by adding Torin2, an ATP-
competitive inhibitor of mTOR (Liu et al., 2011), a combination
that had exhibited efficacy in vitro (A. Azarova and R.E.G.,
unpublished data). When given alone, Torin2 ablated MYCN
tumors with reduction in MYCN protein levels and induction of
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Figure 6. ALKF1174L Promotes Anti-
Apoptotic Activity in ALKF1174L/MYCN
Neuroblastomas
(A) Immunohistochemical staining for Ki67 and
TUNEL of transgenic murine and human
ALKF1174L/MYCN and MYCN neuroblastomas.
Scale bars, 20 mm.
(B) Heat map representation of the expression
levels of pro-survival genes, Bcl2 and Bclw, and
the pro-apoptotic genes Bak, Bax, Bik, Bid, Noxa,
and Trp53, in ALKF1174L/MYCN and MYCN
tumors.
(C) qRT-PCR analysis of Bclw and Bid expression
in ALKF1174L/MYCN and MYCN tumors (n = 10 in
each group). Gene expression is relative to that
in a MYCN tumor. Data are presented as mean ±
SEM (*p = 0.03, **p = 0.005).
(D) Immunoblotting of ALKF1174L/MYCN and
MYCN tumors depicting expression of BCLW,
BCL2, and BID proteins in the ALKF1174L/MYCN
and MYCN tumors.
See also Figure S4.
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Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomaapoptosis (Figures S5A–S5C). However, concomitant expres-
sion of ALKF1174L abrogated any efficacy of Torin2, as indicated
by essentially stable tumor volumes after 7 days of treatment
with this agent at 20mg/kg/day (Figures 7A and 7B). Predictably,
Torin2 treatment of ALKF1174L/MYCN tumors in large part led to
downregulation of themTORC1 targets, pS6K and p4E-BP1, but
did not affect pMEK or pERK, or induce any substantial increase
in apoptosis (Figures 7C and 7D). By contrast, combined use of
crizotinib (100 mg/kg/day) with Torin2 (20 mg/kg/day) for 7 days
significantly reduced tumor size and growth (Figures 7A and 7B).
Of the fourmice receiving both agents, three had obvious regres-
sions of their tumors, while one showed growth inhibition. The
proportion of mice with tumor regression improved to 100% in
a subsequent study in which 80% dosage of each drug was
given in combination (data not shown). These favorable
responses to combination treatment correlated with inhibition
of pALK, pAKT, mTOR, and MAPK targets (Figures 7C and
7D). Importantly, the combination also led to a striking increase
in apoptosis as determined by cleaved caspase-3 staining (Fig-
ure 7D). Since phospho-ALK immunoblotting does not appear to
provide a reliable assessment of ALK inhibition, we confirmed by
mass spectroscopy that crizotinib was present in tumor tissue at
exposure levels in excess of its published IC50 for ALK inhibition
(Bresler et al., 2011; Scho¨nherr et al., 2012) (Table S1). The vari-
ability in total ALK levels on immunoblots of tumors treated with
the combination (Figure 7C) likely reflects the significant levels ofCancer Cell 22, 117–cell death observed at 7 days post-treat-
ment (Figure 7D, H&E stain), and is not
a primary effect of the therapy on ALK
levels. Consistent with this possibility,
immunohistochemical staining of these
tumors showed large regions that stained
negatively for ALK (Figure S5D), and
in tumors harvested after short-term
(3-day) therapy trials, uniform levels of
total ALK were seen on immunoblots
(Figure S5E).We next analyzed longer-term survival using a larger number
of mice (n = 10 per group) treated for 14 days. Treatment with
crizotinib and Torin2 significantly prolonged survival compared
to the outcome with use of vehicle or either single agent alone
(Figure 7E). Indeed, all mice given the combination remained
alive for 10–23 days post-treatment, whereas mice treated with
crizotinib and Torin2 as single agents began to die before treat-
ment was stopped, with none surviving for more than 10 days
post-treatment. Together, these findings suggest that the failure
of crizotinib to inhibit the downstream pathways utilized by
ALKF1174L and MYCN can be overcome by adding an effective
downstream pathway inhibitor, such as Torin2.
DISCUSSION
Activating mutations in the ALK receptor tyrosine kinase repre-
sent potentially useful therapeutic targets in high-risk neuroblas-
toma. In contrast to MYCN, which has been difficult to target
(Gustafson and Weiss, 2010), mutated ALK lends itself to inhibi-
tion by small molecules and hence may spawn a generation of
targeted therapies for this resistant tumor. Hereweused amouse
model of neuroblastoma coexpressing ALKF1174L and MYCN to
demonstrate that constitutive ALKF1174L activity potentiates the
oncogenic effects of MYCN, resulting in the formation of aggres-
sive, highly penetrant tumors. Similar cooperativity between
ALKF1174L and MYCN was recently observed in a zebrafish130, July 10, 2012 ª2012 Elsevier Inc. 125
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Cancer Cell
Mouse Model of ALKF1174L/MYCN-Positive Neuroblastomamodel (Zhu et al., 2012). The acceleration of tumorigenesis by
mutant ALK is accompanied by activation of signaling pathways
that lead to stabilization of theMYCN protein while countering its
pro-apoptotic effects. We also show that our ALKF1174L/MYCN
tumor model recapitulates the in vitro resistance of ALKF1174L–
positive tumor cells to crizotinib, but that the combination of cri-
zotinib and an mTOR inhibitor, Torin2, can circumvent this resis-
tance, leading to marked tumor regression and prolongation of
survival.
ALKF1174L, although shown to be transforming in NIH 3T3 and
Ba/F3 assays (Chen et al., 2008; De Brouwer et al., 2010; George
et al., 2008; Janoueix-Lerosey et al., 2008), did not appear to be
sufficient by itself to induce tumors in our model. The reasons
underlying this are not entirely clear, but given the fact that
ALKmutations have been identified in both high- and low-stage
tumors, it is conceivable that while activated ALK has a role in
tumor initiation, cooperation with additional aberrations such
asMYCN amplification or loss of tumor suppressors on chromo-
some 1p or 11q are required to specify high- versus low-stage
tumors. Serial analysis of developing sympathetic tissues from
Th-ALKF1174L mice will be useful in determining whether neuro-
blast cell hyperplasia or even localized tumors develop in these
animals, which then regress in the absence of cooperative
genetic events.
Of interest, the ALKF1174L mutation has not been reported in
the germline of patients with familial neuroblastoma. This could
indicate that either high levels of activated ALK kinase activity
or functions specific to the ALKF1174L mutation are not tolerated
during embryogenesis. By contrast, we observed Mendelian
distribution of ALKF1174L alleles in crosses of our Th-ALKF1174L
animals suggesting absence of embryonic lethality. The
approach we used to generate our murine model does not
modify the endogenous ALK alleles and therefore the develop-
mentally essential expression of endogenous ALK in the CNS
and other organs (Vernersson et al., 2006) presumably remains
unaltered. Moreover, the Th-driven ALKF1174L mutation exhibits
tissue-specific expression in relatively more differentiated
Th-positive sympathetic neuronal precursors. To more accu-
rately address these issues, a knock-in modeling strategy re-
placing an endogenous Alk allele with an inducible ALKF1174L
allele would be required.
In the Th-MYCN model, heterozygote animals of the 129X1/
SvJ strain develop neuroblastoma within 4 to 5 months accom-
panied by additional chromosomal gains or losses, whereas
homozygous animals show increased penetrance and shorter
latency of tumors that approaches 100% at three months,
without the requirement for additional chromosomal lesions
(Weiss et al., 1997). Thus, a small increase in MYCN dosage is
sufficient to augmentMYCN-driven tumorigenesis.We observed
increased MYCN protein stability in ALKF1174L/MYCN transgenic
tumors. MYCN stability is specifically regulated by sequential
phosphorylation of S62 and T58 within MYC Box 1, the former
through either CDK1 or the MAPK pathway (Marshall et al.,
2011; Sears et al., 2000; Sjostrom et al., 2005), and the latter,
through the PI3K/AKT pathway via GSK3b-mediated inhibitory
phosphorylation (Sears et al., 2000). AKT- or ERK-mediated
mTORC1 signaling also downregulates PP2A, which normally
dephosphorylatesMYCN at S62, targeting pMYCNT58 for ubiqui-
tination and degradation by the E3 ligase FBXW7 (Gustafson andWeiss, 2010). We demonstrate that increased activation of the
PI3K/AKT/mTOR pathway and additional recruitment of the
MAPK pathway combine to stabilize MYCN in ALKF1174L/
MYCN tumors. We suggest that the discrepancy between
MYCN levels on immunohistochemical staining versus immuno-
blotting reflects the very short half-life and high rate of synthesis
of this oncoprotein in vivo. Th-MYCN tumors have very high
levels of MYCN protein even in the absence of ALK expression
(Weiss et al., 1997), and the limited dynamic range of immuno-
blotting may hinder the detection of increased total MYCN by
this method.
We also report that the stabilization of the MYCN protein seen
in ALKF1174L/MYCN tumors is augmented by increased levels of
endogenousMycn transcripts, confirming recent in vitro findings
that both WT and gain of function ALK mutations stimulate
MYCN transcription (Scho¨nherr et al., 2012). The mechanism
underlying this phenomenon is unclear, but could be due to
either an indirect effect of ALKF1174L signaling on the Mycn
promoter (Wierstra and Alves, 2008) or loss ofMycn autorepres-
sion. Indeed, as reported by Penn et al. (Penn et al., 1990), MYC
suppresses transcription from its own promoter when the level
of the oncoprotein exceeds 10,000 molecules per cell. It seems
reasonable, then, to suggest that signaling mediated by
ALKF1174L either prevents or abolishes a block at the Mycn
promoter, allowing unimpeded gene transcription. Such
ALKF1174L-induced regulation of Mycn could occur during early
development, leading to sustained high levels of MYCN in
sympathetic neuronal precursor cells, which then sets the stage
for rapid malignant transformation.
The relative lack of apoptosis in our tumormodel suggests that
ALKF1174L counteracts MYCN-induced cell death as part of the
transformed phenotype. We noted significant downregulation
of the pro-apoptotic BCL2 proteins NOXA, BID, and BAX, all
transcriptional targets of p53, which itself was downregulated
in the ALKF1174L/MYCN tumors. Accompanying these findings
was upregulation of the anti-apoptotic BCLW and, to a lesser
extent, BCL2 proteins. The upregulation of BCLW is particularly
relevant because it has been shown to counteract apoptosis
induced by nerve growth factor deprivation and BAD overex-
pression in sympathetic neuronal cells (Hamne´r et al., 2001).
Moreover, the overexpression of BCLW and BCL2, but not
MCL1, places the ALKF1174L/MYCN tumors in the subset of
neuroblastomas that are predicted to be sensitive to the BCL2
inhibitor ABT-737 (Goldsmith et al., 2010), thus providing an
additional avenue for therapeutic targeting of these tumors. In
other receptor tyrosine kinase-activated cancers and in tumors
positive for ALK fusion proteins, resistance to apoptosis is medi-
ated through signal transduction pathways that directly enhance
the transcription of anti-apoptotic factors such as BCLXL while
inhibiting pro-apoptotic genes (Chiarle et al., 2008). We therefore
suggest that the anti-apoptotic effect seen in ALKF1174L/MYCN
tumors arises from ALKF1174L-mediated activation of both the
PI3K/AKT/mTOR and MAPK signaling cascades.
The demonstration that ALK cooperates withMYCN to accel-
erate tumorigenesis helps to explain the role of oncogenes such
asMYCN during tumor initiation. The bulk of evidence suggests
that MYC oncoproteins play a critical role during this phase of
tumor development, where high levels are required to initiate
and expand oncogenic clones (Arvanitis and Felsher, 2006;Cancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc. 127
Cancer Cell
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apoptotic defect (Hansford et al., 2004). We propose that acti-
vated ALK simultaneously stabilizes MYCN protein and uncou-
plesMYCN-driven apoptosis, potentiating the oncogenic activity
of MYCN during early development of neuroblasts. This concept
is also relevant to the clinical observation that prognosis in
neuroblastoma is strongly associated with MYCN gene copy
number but only variably with protein levels (Cohn et al., 2000).
In contrast to the situation during tumor initiation, low,
‘‘threshold’’ levels of MYC are likely sufficient to maintain
progression of oncogene-addicted, established tumors, and
prevent the switch from ongoing proliferation to apoptosis/
necrosis (Murphy et al., 2008; Shachaf et al., 2008). Therefore,
stabilization of MYCN by modulation of MYC Box 1 phosphory-
lation (Marshall et al., 2011) or inhibition of MYCN protein ubiqui-
tination and degradation (Otto et al., 2009) are both mechanisms
by which stoichiometric control of MYC protein levels are
achieved during malignant transformation in precancerous cells
(Marshall et al., 2011). Pharmacologic modulation of such path-
ways that stabilize MYCN abrogates neuroblastoma tumor
formation in the Th-MYCNmodel, providing experimental valida-
tion of this concept (Chanthery et al., 2012; Marshall et al., 2011).
In MYCN-driven neuroblastoma, the PI3K pathway appears to
be the major signaling conduit for regulation of MYCN activity,
and selective inhibition of this pathway has been shown to lead
to MYCN destabilization and subsequent tumor regression
(Chesler et al., 2006). Oncogenic transformation caused by
ALK fusion proteins, on the other hand, appears to be effected
through several interconnected and overlapping pathways that
are differentially recruited by the activated ALK kinase based
on cell type, context and fusion partner (Chiarle et al., 2008;
Palmer et al., 2009). In anaplastic large cell lymphoma, the aber-
rant growth of the cells expressing theNPM-ALK fusion gene, for
example, ismainly attributable to activation of the JAK-STAT and
MAPK pathways (Pulford et al., 2004). However, in our tumor
model, ALKF1174L utilizes both the PI3K/AKT/mTOR and MAPK
pathways to instigate downstream signals leading to increased
survival. Interestingly, the same signaling pathways are upregu-
lated when the F1174L mutation occurs in the background of
ALK translocations such as EML4-ALK and RANBP2-ALK
(Heuckmann et al., 2011; Sasaki et al., 2010), suggesting that
the same mode of downstream signaling is used whether the
mutation arises de novo or as an acquired mechanism of resis-
tance. Hence, the treatment strategy that we propose, in which
crizotinib is combined with a downstream pathway inhibitor,
may be effective against these cancers, delaying or even pre-
venting the onset of resistance to crizotinib.
For a tyrosine kinase inhibitor to be successful, it must abro-
gate activity of key intracellular pathways that transmit onco-
genic activity of the kinase. We determined that the resistance
to crizotinib seen in ALKF1174L/MYCN-driven murine neuroblas-
toma relates to incomplete inhibition of key signaling cascades.
Crizotinib treatment, while leading to reduced levels of pALK and
pAKT at high doses lacked any effect on pERK or activated
mTOR signaling in ALKF1174L/MYCN tumors. Thus, in crizoti-
nib-treated animals even a minimal amount of ALKF1174L activity
appears sufficient to maintain downstream signaling, especially
that of mTORC1. We suggest that both the PI3K/AKT and MAPK
pathways contribute to mTORC1 activation in these tumors, but128 Cancer Cell 22, 117–130, July 10, 2012 ª2012 Elsevier Inc.as AKT signaling becomes downregulated by crizotinib,
mTORC1 signaling is maintained by the MAPK pathway, which
would account for the relative insensitivity of the tumor cells to
single agent treatment with Torin2. However, combined treat-
ment with crizotinib and Torin2 induced downregulation of all
components of the PI3K/AKT/mTOR aswell asMAPK pathways,
accompanied by the induction of massive apoptosis. Impor-
tantly, suppression of these two signaling pathways, together
with ALKF1174L activity, effectively inhibited the growth of
ALKF1174L/MYCN tumors, leading to significant decreases in
tumor volumes and a higher proportion of surviving mice.
Our study indicates that the combination of crizotinib and an
ATP-competitive mTOR inhibitor, or perhaps a MEK inhibitor,
would afford a useful treatment strategy for neuroblastoma with
constitutive activation of ALKF1174L and MYCN. The reduced
susceptibility of F1174L-mutated ALK to crizotinib inhibition has
been reported to arise from an increased ATP-binding affinity,
suggesting that higher doses of crizotinib or substitution of
higher-affinity inhibitors may surmount this barrier to successful
treatment (Bresler et al., 2011). Although a dose-response rela-
tionship to crizotinib as a single agent in ALKF1174L-expressing
neuroblastoma cell lines (Bresler et al., 2011; A. Azarova and
R.E.G., unpublished data) and in our ALKF1174L/MYCN model
(L.C. and R.E.G., unpublished data) has been observed, whether
the doses of crizotinib required to completely eradicate the tumor
will be feasible in a clinical setting remains to be determined.
Moreover, prolonged use of even themost effective ALK inhibitor
by itself would ultimately generate resistance. Hence, simulta-
neously attacking more than one vulnerable lesion in neuroblas-
toma cells seems a more promising strategy to prevent or fore-
stall the development of crizotinib resistance. Indeed, further
efficacy might be afforded by the addition of therapeutic agents
that inhibit the pro-survival proteins BCL2 and BLCW or that
disruptmechanismsactive in the synthesis ofMYCN.Regardless
of the specific combination of targets, the double transgenic
model developed in this study would provide an ideal platform
for screeningcandidate small-molecule inhibitors andelucidating
interactions among the aberrant signaling cascades that underlie
ALKF1174L/MYCN-positive neuroblastoma. Finally, we suggest
that simultaneous targeting of ALK and its downstream effector
molecules may lengthen the duration of response in a larger
group of patients with tumors harboring crizotinib-sensitive
ALK. This cohort includes those with other point mutations or
amplification of ALK as in neuroblastoma, or with ALK transloca-
tions such as non-small cell lung cancer, inflammatory myofibro-
blastic tumor, anaplastic largecell lymphoma, andseveral others.EXPERIMENTAL PROCEDURES
Plasmids
The ALKF1174L mutation was introduced into WT ALK cDNA in pcDNA3.1
(Invitrogen) using the QuickChange II Site-Directed Mutagenesis Kit (Strata-
gene). All mutations were confirmed by sequencing of the entire ALK open
reading frame. TheALKF1174L cDNAwas ligated downstreamof the rat tyrosine
hydroxylase (Th) promoter (Banerjee et al., 1992) in the Th-MYCN transgenic
construct after excision of MYCN with appropriate restriction enzymes
to generate the p4.5 Th-ALKF1174L construct. For transient transfections,
ALKF1174L was introduced into 293T cells (human embryonic kidney trans-
formed cells) using Fugene 6 transfection reagent (Roche) according to the
manufacturer’s instructions.
Cancer Cell
Mouse Model of ALKF1174L/MYCN-Positive NeuroblastomaMouse Models
Th-ALKF1174L founders were derived from CBA 3 C57BL/6J mice and genet-
ically crossedwith Th-MYCNmice of the 129/SvJ strain. Tail DNA of all animals
was analyzed for ALK and MYCN transgenes by qRT-PCR (Transnetyx, Inc.).
All animal experiments were conducted in accordance with established UK
HomeOffice guidelines per conditions specified in an animal use authorization
license (PPL70-6882) that is approved by The Institute of Cancer Research
local ethical review committee.
Tumor Histopathology
Animal tumors were harvested at sacrifice, fixed in 10% neutral buffered
formalin, and paraffin-embedded for histologic studies. Tissue sections were
stained with H&E and assessed histologically by a pediatric pathologist
(A.P.A.) for confirmation of tumor type, and specifically for histologic features
of neuroblastoma including amount of stroma and neuropil, mitotic/karyor-
rhectic index, and degree of differentiation. Representative examples from
each of the founder lines were analyzed (ALKF1174L/MYCN tumors, n = 15;
MYCN tumors, n = 9). For immunohistochemistry, 5 mm sections were stained
with antibodies to ALK (Ventana), MYCN (Calbiochem), pMEK, pS6K, pERK,
cleaved caspase 3 (Cell Signaling Technology), and TUNEL (Millipore) using
standard methods, including heat-induced epitope retrieval using citrate
buffer pH 6 (or EDTA buffer for ALK). Formalin-fixed slides from patients with
both ALKF1174L/MYCN-positive and MYCN-positive neuroblastoma tumors
were stained using the same antibodies. All human tumor specimens were
obtained in accordance with the Institutional Review Boards of Memorial
Sloan-Kettering Cancer Center and the Dana-Farber Cancer Institute and
deidentified before analysis.
Murine Therapy Trials
Th-MYCN hemizygous mice were bred with Th-ALKF1174L hemizygous mice,
and litters were genotyped to detect the presence of human MYCN or
ALKF1174L transgenes. After weaning, at about day 28, animals hemizygous
for both transgenes orMYCN alone were palpated for intra-abdominal tumors
twice weekly. Animals with palpable tumors (30–70 days old) were randomized
to treatment groups. For intervention trials, mice were treated with 100 mg/kg
crizotinib or 20 mg/kg Torin2 as single agents, 100 mg/kg crizotinib and
20 mg/kg Torin2 in combination, or vehicle for 7 days. Crizotinib and Torin2
were administered via oral gavage. MRI was performed on a 7T Bruker hori-
zontal bore microimaging system (Bruker Instruments, Ettlingen, Germany)
using a 3-cm birdcage coil. Anatomical T2-weighted coronal images were
acquired from twenty contiguous 1 mm thick slices through the mouse
abdomen, from which tumor volumes were determined using segmentation
from regions of interest drawn on each tumor-containing slice. At sacrifice,
tumors were excised, weighed, snap frozen in liquid nitrogen for metabolic
assays, or fixed in 10% neutral buffered formalin. For survival trials, mice
were treated with 100 mg/kg crizotinib or 20 mg/kg Torin2 as single agents,
100 mg/kg crizotinib (or 80 mg/kg where indicated) and 20 mg/kg Torin2 in
combination, or vehicle for 14 days. Mice were monitored daily; tumor size
was palpated and animal weights measured. Animals were sacrificed when
pathologic signs of tumor burden (predominantly poormobility) were apparent.
Statistical Analyses
All biochemical experiments were done in triplicate unless otherwise stated.
Two-tailed Student’s t test was used to test significance. Survival curves
were constructed by the Kaplan and Meier method, with differences between
curves tested for statistical significance using the log-rank test; s.d., standard
deviation; C.I., confidence interval; s.e.m., standard error of the mean.
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